Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASP 0892

Drug Profile

ASP 0892

Alternative Names: ARA h1,2,3-Lamp-vax peanut vaccine; ARA-LAMP-Vax™; ASP0892; Peanut allergy vaccine - Immunomic

Latest Information Update: 28 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomic Therapeutics
  • Developer Astellas Pharma
  • Class DNA vaccines; Food allergy immunotherapies
  • Mechanism of Action Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Peanut hypersensitivity

Most Recent Events

  • 28 Nov 2019 No recent reports of development identified for phase-I development in Peanut-hypersensitivity(Prevention) in USA (IM)
  • 28 Nov 2019 No recent reports of development identified for phase-I development in Peanut-hypersensitivity(Prevention) in USA (Intradermal)
  • 04 Jan 2019 Phase-I clinical trials in Peanut hypersensitivity (In adolescents, Prevention) in USA (Intradermal) (NCT03755713)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top